Related Experiment Video
Updated: Jul 8, 2025
08:57
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
2.0K
POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA
Sh Nishikawa1, T Hayashi2, T Uzaki3
11Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Centre, Japan.
Georgian Medical News
|December 14, 2023
Summary
Diagnosing uterine mesenchymal tumors like leiomyosarcoma is challenging due to varied cell morphologies. Molecular techniques like gene expression profiling offer new hope for accurate prediction and treatment of these tumors.
Area of Science:
- Gynecologic Oncology
- Pathology
- Molecular Diagnostics
Background:
- Uterine mesenchymal tumors, including benign leiomyoma and malignant leiomyosarcoma, are difficult to diagnose due to overlapping cell morphologies.
- Specific subtypes like cotyledonoid dissecting leiomyoma and smooth muscle tumors of uncertain malignant potential present diagnostic challenges.
- Current diagnostic methods lack standardization and definitive preoperative tools, especially for patients desiring future pregnancy.
Purpose of the Study:
- To investigate the oncological properties of uterine smooth muscle tumors of uncertain malignant potential (STUMPs) using molecular pathological techniques.
- To identify factors associated with malignancy in uterine mesenchymal tumors through gene expression profiling.
- To highlight diagnostic challenges and present recent clinical findings for uterine mesenchymal tumors.
Main Methods:
- Analysis of oncological properties of STUMPs using molecular pathological techniques on excised tumor tissue.
- Examination of gene expression profiling in a clinical study of adult patients with uterine mesenchymal tumors.
- Review of existing literature on diagnostic challenges and biomarker utility.
Main Results:
- Gene expression profiling identified potential factors associated with the malignancy of uterine mesenchymal tumors.
- Existing immunohistochemical biomarkers have shown limited efficacy in determining the malignant potential of STUMPs.
- No established correlation between current biomarkers and mitotic rate or tumor recurrence has been found.
Conclusions:
- Accurate diagnosis and differentiation of uterine mesenchymal tumors remain a significant clinical challenge.
- Next-generation molecular techniques, such as gene expression profiling, are crucial for improving disease prediction, diagnosis, and prognosis.
- Developing targeted diagnostic methods for mesenchymal tumor cells is expected to enable effective treatment of malignant tumors with reduced recurrence and metastasis risk.
